Back to search results

A Study of ABBV-1451 in Healthy Adults

This study is looking for healthy adult volunteers, aged 18 to 60, to help us understand a new drug called ABBV-1451. We want to learn how your body handles ABBV-1451 (pharmacokinetics or PK) when given as an injection or an infusion (into a vein). We also want to see if it's safe and how well people tolerate it. Some participants will receive ABBV-1451, while others will receive a placebo (an inactive substance). The study will measure side effects and how much ABBV-1451 is in your blood over about 211 days. The study aims to enroll 90 participants, but its current recruitment status is unclear.

Study design
This is an interventional study involving single ascending doses of ABBV-1451 or placebo, given as injections or infusions, to approximately 90 healthy adult participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and drug levels for up to approximately 211 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07570147

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

Recruiting
PHASE1Ages 18–60InterventionalBasic science
AbbVie
~90 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:ABBV-1451Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs)
Measured over Up to Approximately Day 211
+6 more outcomes measured

Conditions

Healthy Volunteer

Explore related trials

Healthy Volunteer

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

ABBVIE CALL CENTER
[email protected]
844-663-3742
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
Applies to Part 2 only:
For Japanese participants:
For Han Chinese participants:
Participant must be first or second-generation Han Chinese of full Chinese parentage, residing outside of China. First generation participants will have been born in China to two parents and four grandparents also born in China of full Chinese descent. Second-generation participants born outside of China must have two parents and four grandparents born in China of full Chinese descent. Participants must be in general good health.

Exclusion

History: of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
History of any clinically significant sensitivity or allergy to any medication or food.
History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.

What this trial measures

  • Number of Participants with Adverse Events (AEs)Up to Approximately Day 211

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

  • Maximum Observed Plasma Concentration (Cmax) of ABBV-1451Up to Approximately Day 211

    Cmax of ABBV-1451.

  • Time to Cmax (Tmax) of ABBV-1451Up to Approximately Day 211

    Tmax of ABBV-1451.

  • Terminal Phase Elimination Rate Constant (β) of ABBV-1451Up to Approximately Day 211

    β of ABBV-1451.

  • Terminal Phase Elimination Half-Life (t1/2) of ABBV-1451Up to Approximately Day 211

    t1/2 of ABBV-1451.

  • Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-1451Up to Approximately Day 211

    AUCt of ABBV-1451.

  • Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-1451Up to Approximately Day 211

    AUCinf of ABBV-1451.